Nephros (NEPH) director Arthur Amron granted 2,418 shares, holds 140,874
Rhea-AI Filing Summary
Nephros Inc. director Arthur H. Amron received 2,418 shares of Common Stock on 2026-08-12 as a grant in lieu of cash fees for board service, bringing his direct Common Stock holdings to 140,874 shares. He also holds stock options to acquire 7,323 shares of Common Stock at an exercise price of $2.14 per share that are fully vested, and additional options for 7,050 shares at an exercise price of $1.47 per share that vest in three equal installments of 2,350 shares on 1/1/25, 1/1/26 and 1/1/27.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 2,418 shares
Net Buy
3 txns
Insider
Amron Arthur H
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1 | 2,418 | $0.00 | $0.00 |
| holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F3 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 140,874 shares (Direct);
Stock Option (Right to Buy) — 14,373 shares (Direct)
Footnotes (3)
- F1. Shares issued to reporting person in lieu of cash fees for board service.
- F2. Fully vested.
- F3. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27.
Key Figures
Common Stock grant: 2,418 shares
Holdings after grant: 140,874 shares
Option exercise price: $2.14 per share
+3 more
6 metrics
Common Stock grant
2,418 shares
Shares issued on 2026-08-12 in lieu of cash fees for board service
Holdings after grant
140,874 shares
Total direct Common Stock owned by Arthur H. Amron following the grant
Option exercise price
$2.14 per share
Exercise price for fully vested stock option on 7,323 underlying Common shares
Option exercise price
$1.47 per share
Exercise price for stock option on 7,050 underlying Common shares vesting 2025-2027
Underlying shares (fully vested option)
7,323 shares
Common Stock underlying fully vested stock option at $2.14 per share
Underlying shares (vesting option)
7,050 shares
Common Stock underlying option at $1.47 per share vesting in three 2,350-share tranches
Key Terms
in lieu of cash fees, fully vested, Stock Option (Right to Buy), exercise price, +1 more
5 terms
in lieu of cash fees financial
"Shares issued to reporting person in lieu of cash fees for board service."
fully vested financial
"Fully vested."
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with underlying Common Stock and exercise price."
exercise price financial
"exercise price of $2.1400 and $1.4700 per share on stock options."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
underlying security financial
"underlying security shares of Common Stock for the stock options."
FAQ
What did Nephros (NEPH) director Arthur H. Amron report in this Form 4?
Arthur H. Amron reported a grant of 2,418 shares of Nephros Common Stock on 2026-08-12, received in lieu of cash fees for board service, increasing his direct Common Stock holdings to 140,874 shares.
What stock options in Nephros (NEPH) does Arthur H. Amron hold?
Arthur H. Amron holds options to acquire 7,323 shares of Nephros Common Stock at $2.14 per share, which are fully vested, and additional options for 7,050 shares at $1.47 per share with a stated vesting schedule.
What is the vesting schedule for Arthur H. Amron’s Nephros (NEPH) options at $1.47?
The option covering 7,050 shares at an exercise price of $1.47 per share vests as to 2,350 shares on each of 1/1/25, 1/1/26, and 1/1/27, according to the disclosed vesting footnote.
AI-generated analysis. How Rhea-AI works. Not financial advice.
